Primary tumor resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival

Turner, N; Tran, B; Tran, PV; Sinnathamby, M; Wong, HL; Jones, I; Croxford, M; Desai, J; Tie, J; Field, KM; Kosmider, S; Bae, S; Gibbs, P

Author(s): Turner, N; Tran, B; Tran, PV; Sinnathamby, M; Wong, HL; Jones, I; Croxford, M; Desai, J; Tie, J; Field, KM; Kosmider, S; Bae, S; Gibbs, P;
Details: Publication Year 2015-09,Volume 14,Issue #3,Page 185-191
Journal Title: Clin Colorectal Cancer
Publication Type: Journal Article
Abstract: BACKGROUND: The true survival benefit of noncurative primary tumor resection in patients with de novo metastatic colorectal cancer (mCRC) remains uncertain. The present study examined the effect of primary tumor resection on systemic inflammation and survival in patients with mCRC. MATERIALS AND METHODS: Consecutive patients with de novo mCRC who had undergone primary tumor resection were identified from a prospective database. Patients were excluded if they had undergone resection of metastases, had undergone delayed primary resection, or if blood samples were unavailable. The neutrophil/lymphocyte ratio (NLR) was used as a biomarker of systemic inflammation. Overall survival (OS) was compared between patient groups according to the pre- and postprimary resection NLR. The associations between the reversal of an elevated NLR and primary tumor bulk or performance status were explored. RESULTS: A total of 145 eligible patients were identified from the database, with a median age of 70 years. The baseline NLR was elevated (> 5) in 65 patients, 36 (55%) of whom had a low NLR after surgery. The reversal of an elevated NLR was associated with significantly improved OS (hazard ratio, 0.53; P = .017). A similar benefit was seen after excluding patients undergoing emergency primary resection. NLR reversal was more frequent in patients with larger primary tumors or good performance status. CONCLUSION: The present study is the first to demonstrate a relationship between the reversal of a systemic inflammatory response and the improved survival after primary resection in those with mCRC. A greater effect was seen in patients with large primary tumors. If validated, these observations could guide clinical decision-making in patients with mCRC at presentation.
Publisher: Elsevier
Research Division(s): Systems Biology And Personalised Medicine
PubMed ID: 25882598
Publisher's Version: https://doi.org/10.1016/j.clcc.2015.02.004
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2015-05-20 10:11:27

Last Modified: 2015-08-13 03:16:52